antibody – media

Funds of £1.5 million raised by UK-based life sciences group

With a view to augment business activities and help improve product outreach; a UK-based life sciences firm has raised £1.5 million.
- Source: drugdu
- 827
- May 10, 2018
antibody Company Insights
XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer

XBiotech USA, Inc. (NASDAQ:XBIT) announced today that it has obtained an exclusive, worldwide license from CT Atlantic AG (CTA), a Swiss biotechnology company. Under the terms of the license agreement, XBiotech will use its proprietary manufacturing technology to advance the development of the True HumanTM anti-NY-ESO-1 monoclonal antibody, 12D7.
- Source: Forextv
- 888
- April 18, 2018
12D7 antibody Market Views
RubrYc Therapeutics Completes $10M Million Series A Financing

RubrYc Therapeutics, Inc., a biotherapeutics discovery business, announced today it has closed a $10 million Series A Preferred Equity financing round led by Third Point Ventures, with participation by Paladin Capital Group and Vital Venture Capital.
- Source: prnewswire
- 928
- April 16, 2018
antibody biotherapeutics Series
TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ®) and TESARO’s PARP-inhibitor ZEJULA® (niraparib) in patients with metastatic bladder cancer.
- Source: ir.tesarobio
- 771
- March 6, 2018
antibody bladder cancer Market Views oncology
Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs

Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, today announced the completion of a $58 million Series A financing. This funding will be used to advance its initial drug programs for autoimmune and inflammatory diseases toward the clinic, as well as to continue building the company’s technology platform and pipeline. Polaris Partners, the founding investor that provided the initial seed funding, co-led the Series A financing along with Versant Ventures and Roche Venture Fund. SR One and BioInnovation Capital also participated in the round.
- Source: finance.yahoo
- 897
- January 22, 2018
antibody Company Insight immunomodulation
Watch out Sanofi–Takeda’s new data on dengue vaccine is good news for PhIII trial

Prospects for Takeda’s dengue vaccine just turned brighter following fresh data from the company’s Phase II trial. For Takeda, the data is likely welcome considering the company already has a massive pivotal trial underway for the vaccine. For competitor Sanofi … perhaps not so welcome.
- Source: endpts
- 941
- November 7, 2017
antibody dengue Phase vaccine
How flu shot manufacturing forces influenza to mutate

According to a new study from scientists at The Scripps Research Institute (TSRI), the common practice of growing influenza vaccine components in chicken eggs disrupts the major antibody target site on the virus surface, rendering the flu vaccine less effective in humans.
- Source: Medicalxpress
- 853
- October 31, 2017
antibody influenza vaccine
US regulators wave through Pfizer’s leukaemia drug

Pfizer’s Besponsa has been approved by the US Food and Drug Administration (FDA). It's the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
- Source: pharmatimes
- 1,043
- August 21, 2017
ALL antibody Company Insight FDA New Approvals
MRC links with UCB in antibody initiative

The Medical Research Council (MRC) and UCB have launched a new scheme designed to help accelerate work on the development of antibody-based therapeutics.
- Source: pharmatimes
- 853
- August 4, 2017
antibody Company Insight Researches
EU regulators review Novartis’ migraine drug

An experimental therapy being developed by Amgen and Novartis to prevent migraine has been accepted for review in the European Union.
- Source: pharmatimes
- 1,001
- June 22, 2017
antibody Clinical Trials erenumab EU New Approvals WHO

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.